Related Experiment Video
Updated: Mar 16, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
Addressing the Challenges of Hepatitis C Virus Resistance and Treatment Failure
Che C Colpitts1,2, Thomas F Baumert3,4,5
1Institut de Recherche sur les Maladies Virales et Hépatiques, Inserm, U1110, 3 rue Koeberlé, 67000 Strasbourg, France. colpitts@unistra.fr.
Abstract:
Chronic hepatitis C is a major cause of chronic liver disease, including liver cirrhosis and hepatocellular carcinoma. The development of direct-acting antivirals (DAAs) revolutionized hepatitis C virus (HCV) treatment by offering genuine prospects for the first comprehensive cure of a chronic viral infection in humans. While antiviral resistance is a significant limitation for interferon-based therapies, resistance and treatment failure still appear to be present in a small fraction of patients even in state-of-the-art DAA combination therapies. Therefore, treatment failure and resistance still remain a clinical challenge for the management of patients not responding to DAAs. In this special issue of Viruses on HCV drug resistance, mechanisms of antiviral resistance for different classes of antiviral drugs are described. Furthermore, the detection and monitoring of resistance in clinical practice, the clinical impact of resistance in different patient groups and strategies to prevent and address resistance and treatment failure using complementary antiviral strategies are reviewed.
More Related Videos
Related Concept Videos
Retrovirus Life Cycles
Treatment Resistant Cancers
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

